Abcam Future Growth

Future criteria checks 4/6

Abcam is forecast to grow earnings and revenue by 39.3% and 13% per annum respectively. EPS is expected to grow by 39.1% per annum. Return on equity is forecast to be 15.3% in 3 years.

Key information

39.3%

Earnings growth rate

39.1%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	13.0%
Future return on equity	15.3%
Analyst coverage	Low
Last updated	06 Dec 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:ABCM - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	519	111	157	200	4
12/31/2024	467	81	150	171	5
12/31/2023	421	53	98	137	5
6/30/2023	380	3	-21	26	N/A
3/31/2023	371	-3	-17	27	N/A
12/31/2022	362	-8	-13	29	N/A
9/30/2022	356	-1	-1	42	N/A
6/30/2022	350	7	12	55	N/A
3/31/2022	333	6	7	59	N/A
12/31/2021	315	4	3	63	N/A
6/30/2021	298	16	15	72	N/A
3/31/2021	284	7	14	65	N/A
12/31/2020	295	26	18	67	N/A
9/30/2020	265	5	20	60	N/A
6/30/2020	260	13	27	63	N/A
3/31/2020	267	27	31	67	N/A
12/31/2019	273	43	36	73	N/A
9/30/2019	267	44	33	72	N/A
6/30/2019	260	44	30	69	N/A
3/31/2019	253	51	25	69	N/A
12/31/2018	245	58	21	67	N/A
9/30/2018	239	60	23	65	N/A
6/30/2018	233	62	26	63	N/A
3/31/2018	230	59	35	64	N/A
12/31/2017	227	55	44	64	N/A
9/30/2017	222	49	46	65	N/A
6/30/2017	217	42	47	66	N/A
3/31/2017	206	41	N/A	64	N/A
12/31/2016	196	40	N/A	62	N/A
9/30/2016	184	39	N/A	55	N/A
6/30/2016	172	37	N/A	47	N/A
3/31/2016	164	37	N/A	45	N/A
12/31/2015	156	37	N/A	43	N/A
9/30/2015	150	37	N/A	41	N/A
6/30/2015	144	37	N/A	40	N/A
3/31/2015	138	36	N/A	42	N/A
12/31/2014	133	35	N/A	45	N/A
9/30/2014	130	35	N/A	43	N/A
6/30/2014	128	34	N/A	41	N/A
3/31/2014	127	34	N/A	39	N/A
12/31/2013	127	34	N/A	36	N/A
9/30/2013	125	33	N/A	38	N/A
6/30/2013	122	33	N/A	39	N/A
3/31/2013	116	30	N/A	34	N/A
12/31/2012	110	28	N/A	29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABCM's forecast earnings growth (39.3% per year) is above the savings rate (2.2%).

Earnings vs Market: ABCM's earnings (39.3% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: ABCM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ABCM's revenue (13% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: ABCM's revenue (13% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABCM's Return on Equity is forecast to be low in 3 years time (15.3%).

Abcam Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Abcam plc Provides Revenue Guidance for the First Half Ending June 30, 2023

Abcam plc Provides Revenue Guidance for Fy2023 and Fy2024

Abcam plc Reiterates Earnings Guidance for the Years 2023 and 2024

Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022

Recent updates

Abcam Files Form 15

Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Jonathan Milner Continues Opposition to Danaher Corporation Acquisition

Jonathan Milner Releases Presentation to Abcam plc Shareholders

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner issues Open Letter to Shareholders of Abcam plc

Jonathan Milner Opposes Danaher's Acquisition of Abcam

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion.

Jonathan Milner Sends an Open Letter to Abcam plc

Abcam plc Provides Revenue Guidance for the First Half Ending June 30, 2023

Jonathan Milner Announces Suspension of Proxy Solicitation

Abcam plc Provides Revenue Guidance for Fy2023 and Fy2024

Jonathan Milner Issues an Open Letter to shareholders of Abcam plc

Jonathan Milner Sends a Letter to Abcam plc

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner Calls Extraordinary General Meeting to Replace Directors at Abcam

Abcam plc Reiterates Earnings Guidance for the Years 2023 and 2024

Abcam plc to Report Fiscal Year 2022 Results on Mar 20, 2023

Abcam Provides Update on AIM Delisting

Abcam plc Announces Proposed Cancellation of AIM Shares

Abcam: A Good Growth Stock In The Healthcare Market

Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022

Abcam plc Appoints Luba Greenwood as Non-Executive Director

Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2M

Abcam Board Decides to Pursue A Proposal to Cancel the Admission of the Shares to Trading on Aim

Abcam plc to Report First Half, 2022 Results on Sep 12, 2022

Abcam plc, Annual General Meeting, May 18, 2022

Abcam plc to Report 18 Months Period Ending Dec 31, 2021 Results on Mar 14, 2022

Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021

Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Abcam: A Promising Business Model In The Drug Industry

Abingdon Health Signs Collaboration and Co-Marketing Agreement with Abcam

Abcam plc Appoints Non-Executive Directors

Abcam rallies on 1H trading update

Abcam plc to Report Q2, 2021 Results on Mar 08, 2021

Abcam plc, Annual General Meeting, Dec 04, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies